Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
A Propensity-Matched Cohort Study on Angiotensin-converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Therapy in Transthyretin Amyloid Cardiomyopathy
Session:
Sessão de Posters 42 - Para além da hipertrofia: as faces ocultas da doença miocárdica
Speaker:
Emídio Mata
Congress:
CPC 2026
Topic:
K. Cardiovascular Disease In Special Populations
Theme:
30. Cardiovascular Disease in Special Populations
Subtheme:
30.14 Cardiovascular Disease in Special Populations - Other
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Emídio Mata; Luísa Pinheiro; Margarida Castro; Bárbara Lage Garcia; Tamara Pereira; Filipa Cordeiro; Olga Azevedo; António Lourenço
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:11.0pt">Background:</span></strong><span style="font-size:11.0pt"> Evidence supporting the use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ACEI/ARB) in heart failure (HF) due to transthyretin amyloid cardiomyopathy (ATTR-CM) remains limited.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:11.0pt">Aim:</span></strong><span style="font-size:11.0pt"> To evaluate the association between ACEI/ARB therapy and clinical outcomes in patients with ATTR-CM.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:11.0pt">Methods:</span></strong><span style="font-size:11.0pt"> We performed a single-center, retrospective cohort study of consecutive patients with confirmed ATTR-CM diagnosed between 2014 and 2023 (n=110). Patients were classified as ACEI/ARB-treated or untreated. Propensity score (PS) matching using 12 clinical covariates yielded 28 matched pairs (n=56). The primary endpoint was all-cause mortality; secondary endpoints included HF hospitalization (HFH) and a composite of mortality and HFH. Outcomes were assessed with Kaplan–Meier estimates and Cox proportional hazards models with treatment assigned at baseline.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:11.0pt">Results: </span></strong><span style="font-size:11.0pt">In the PS-matched cohort (mean age 81.0±4.6 years; 61.5% male), ACEI/ARB therapy was not associated with a reduction in all-cause mortality (HR 0.86 [0.42–1.78], p=0.684) over a median follow-up of 23 months (IQR 16–41.25). Similar results were observed in the unmatched cohort (HR 0.61 [0.34–1.12], p=0.112). The annualized mortality rate was comparable between treated and untreated patients (14.4% vs 16.6% per person-year).</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><span style="font-size:11.0pt">ACEI/ARB therapy was also not associated with a reduction in HF hospitalization. The PS-matched HR for HFH was 0.74 [0.27–2.03] (p=0.56), consistent with the unmatched cohort (HR 0.52 [0.26–1.05], p=0.07). Annualized HFH rates were similar between groups (9.9% vs 12.5% per person-year).</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><span style="font-size:11.0pt">The composite of all-cause mortality or HF hospitalization showed no significant difference in either the unmatched (HR 0.58 [0.32–1.05], p=0.07) or PS-matched cohort (HR 0.75 [0.32–1.77], p=0.51). Annualized composite event rates were likewise similar (14.9% vs 18.9% per person-year).</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Aptos,sans-serif"><strong><span style="font-size:11.0pt">Conclusions:</span></strong><span style="font-size:11.0pt"> In this propensity-matched cohort of patients with ATTR-CM, ACEI/ARB therapy was not associated with improvements in all-cause mortality, HF hospitalization, or the composite of these outcomes. These findings suggest that ACEI/ARB therapy may not confer meaningful clinical benefit in the ATTR-CM population and highlight the need for prospective research to clarify optimal medical management in this disease.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site